Protillion Biosciences, Inc. has signed a multi-target discovery collaboration and license agreement with Merck, the pharmaceutical giant known as MSD outside the United States, according to an announcement published on Yahoo Finance.
Protillion describes itself as a leader in what it calls "lab-in-the-loop" AI drug design — an approach that combines artificial intelligence with real laboratory experimentation in a continuous feedback cycle, rather than relying on AI predictions alone.
The deal is framed as a multi-target collaboration, meaning the two companies will work together to identify and develop drug candidates across more than one disease target simultaneously. Financial terms of the agreement were not disclosed in the announcement.
The partnership reflects a broader trend in the pharmaceutical industry: large drugmakers are increasingly turning to AI-native biotech startups to accelerate the earliest, most expensive stages of drug discovery, where most candidates fail. Traditional drug discovery can take years and cost hundreds of millions of dollars before a single compound advances to clinical trials.
For Protillion, the Merck deal represents a significant validation of its platform. For Merck, partnering with a specialized AI firm offers a way to explore multiple targets faster than conventional methods might allow.
If AI-assisted approaches can reliably identify better drug candidates earlier, it could meaningfully shorten the time it takes to bring new medicines to patients.